National Taiwan Universtiy Hospital

Taipei 100

1 studies enrolling now · 4 studies all time

What they study most

Lymphoma, Non-Hodgkin's Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Relapsed or Refractory Follicular Lymphoma

Studies at this site

• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma — Recruiting now
• A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma — Running, not enrolling
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma — Running, not enrolling